Sichuan Kelun-Biotech Biopharmaceutical Co Ltd
Company Profile
Business description
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd is a biopharmaceutical company committed to the R&D, manufacturing, and commercialization of novel drugs to address medical needs in China and globally. It is one of the first movers in the development of antibody-drug conjugates (ADCs), with over a decade of accumulated experience in ADC development. The company takes a systematic, indication-oriented approach to target the world's prevalent or hard-to-treat cancers, and other diseases and conditions affecting a large and underserved population. Currently, the company has two ADC drugs as Core Products, namely, sac-TMT and trastuzumab botidotin.
Contact
No. 666 Xinhua Avenue
Chengdu Cross-Strait Science and Technology Industry Development Park
Wenjiang
Sichuan
Chengdu
CHNT: +86 4006887002
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
2,045
Stocks News & Analysis
stocks
Older cohorts the budget losers, not necessarily the ASX listed insurers
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,829.50 | 17.30 | 0.20% |
| CAC 40 | 8,013.62 | 26.13 | 0.33% |
| DAX 40 | 24,483.27 | 175.35 | 0.72% |
| Dow JONES (US) | 49,515.78 | 170.34 | -0.34% |
| FTSE 100 | 10,339.86 | 16.11 | 0.16% |
| HKSE | 25,797.85 | 122.67 | 0.48% |
| NASDAQ | 25,721.49 | 369.25 | -1.42% |
| Nikkei 225 | 60,550.59 | 265.36 | -0.44% |
| NZX 50 Index | 12,974.32 | 211.40 | 1.66% |
| S&P 500 | 7,338.80 | 64.25 | -0.87% |
| S&P/ASX 200 | 8,604.70 | 23.10 | 0.27% |
| SSE Composite Index | 4,169.54 | 38.01 | 0.92% |